Cargando…

Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation

BACKGROUND: Approximately 15% of lung cancer patients are diagnosed in early stages. Microscopic proof of disease cannot always be obtained because of comorbidity or reluctance to undergo invasive diagnostic procedures. In the current study, survival data of patients with and without pathology are c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zehentmayr, Franz, Sprenger, Martin, Rettenbacher, Lukas, Wass, Romana, Porsch, Peter, Fastner, Gerd, Pirich, Christian, Studnicka, Michael, Sedlmayer, Felix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360228/ https://www.ncbi.nlm.nih.gov/pubmed/30618120 http://dx.doi.org/10.1111/1759-7714.12966

Ejemplares similares

Pulmonary function decreases moderately after accelerated high‐dose irradiation for stage III non‐small cell lung cancer
por: Grambozov, Brane, et al.
Publicado: (2019)

Impact of reirradiation, chemotherapy, and immunotherapy on survival of patients with recurrent lung cancer: A single‐center retrospective analysis
por: Grambozov, Brane, et al.
Publicado: (2021)

Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis
por: Grambozov, Brane, et al.
Publicado: (2021)

Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review
por: Zehentmayr, Franz, et al.
Publicado: (2020)

Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid)
por: Zehentmayr, Franz, et al.
Publicado: (2015)

DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)–a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume
por: Wurstbauer, Karl, et al.
Publicado: (2013)

Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer
por: Rendl, Gundula, et al.
Publicado: (2014)

High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
por: Grambozov, Brane, et al.
Publicado: (2022)

Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity
por: Wass, Romana, et al.
Publicado: (2022)

DART-bid for loco-regionally advanced NSCLC: Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints
por: Wurstbauer, Karl, et al.
Publicado: (2017)

Intraoperative radiotherapy (IORT) as boost in breast cancer
por: Sedlmayer, Felix, et al.
Publicado: (2017)

Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III
por: Stana, Markus, et al.
Publicado: (2022)

Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DL(CO) Correlate with Radiation Dosimetry and Pneumonitis Rate
por: Stana, Markus, et al.
Publicado: (2023)

Reply to: The challenge of cardiac dose constraint adaptation to hypofractionated breast radiotherapy in clinical practice
por: Piroth, Marc D., et al.
Publicado: (2021)

Boost IORT in Breast Cancer: Body of Evidence
por: Sedlmayer, Felix, et al.
Publicado: (2014)

Nonmetastatic pancreatic cancer: Improved survival with chemoradiotherapy > 40 Gy after systemic treatment
por: Bachmayer, Sebastian, et al.
Publicado: (2018)

miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites
por: Rinnerthaler, Gabriel, et al.
Publicado: (2016)

Hsa-miR-375 is a predictor of local control in early stage breast cancer
por: Zehentmayr, Franz, et al.
Publicado: (2016)

Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer
por: Zellinger, Barbara, et al.
Publicado: (2020)

Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3
por: Zellinger, Barbara, et al.
Publicado: (2021)

IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study
por: Ciabattoni, Antonella, et al.
Publicado: (2021)

Correction to: IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study
por: Ciabattoni, Antonella, et al.
Publicado: (2021)

DEGRO practical guidelines: radiotherapy of breast cancer I: Radiotherapy following breast conserving therapy for invasive breast cancer
por: Sedlmayer, F., et al.
Publicado: (2013)

(18)F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with (99m)Tc-MIBI or (99m)Tc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients
por: Beheshti, Mohsen, et al.
Publicado: (2018)

First clinical application of image-guided intraoperative electron radiation therapy with real time intraoperative dose calculation in recurrent rectal cancer: technical procedure
por: Roeder, Falk, et al.
Publicado: (2023)

Successful Bronchoscopic Cryorecanalization in a Case of Endobronchial Lipoma
por: Lamprecht, B., et al.
Publicado: (2011)

Pathology-confirmed versus non pathology-confirmed cancer diagnoses: incidence, participant characteristics, and survival
por: van der Willik, Kimberly D., et al.
Publicado: (2019)

Safe application of extensive radiotherapy to a cardiac resynchronization device
por: Schernthaner, Christiana, et al.
Publicado: (2020)

Cerebral cortex dose sparing for glioblastoma patients: IMRT versus robust treatment planning
por: Exeli, Ann-Katrin, et al.
Publicado: (2018)

Fluorodeoxyglucose positron emission tomography (FDG/PET) shows the effect of carbon-ion radiotherapy (CIRT); with pathologic confirmation
por: Aoki, Jun, et al.
Publicado: (2023)

Preoperative external beam radiotherapy and reduced dose brachytherapy for carcinoma of the cervix: survival and pathological response
por: Jacinto, Alexandre A, et al.
Publicado: (2007)

Infliximab treatment in pathology-confirmed neurosarcoidosis
por: Fritz, Daan, et al.
Publicado: (2020)

Model-independent confirmation of the $Z(4430)^-$ state
por: Aaij, Roel, et al.
Publicado: (2015)

Hypofractionated Whole Breast Irradiation and Boost-IOERT in Early Stage Breast Cancer (HIOB): First Clinical Results of a Prospective Multicenter Trial (NCT01343459)
por: Fastner, Gerd, et al.
Publicado: (2022)

Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy
por: Hallqvist, A., et al.
Publicado: (2012)

Radiotherapy for esophageal carcinoma: dose, response and survival
por: Luo, Yijun, et al.
Publicado: (2017)

Current controversies in radiotherapy for breast cancer
por: Krug, David, et al.
Publicado: (2017)

Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature
por: Leitinger, Markus, et al.
Publicado: (2018)

Oligometastasis in breast cancer—current status and treatment options from a radiation oncology perspective
por: Piroth, Marc D., et al.
Publicado: (2022)

Effect of postoperative radiotherapy on survival in patients with completely resected and pathologically confirmed stage N2 non-small-cell lung cancer: a systematic review and meta-analysis
por: Wang, Lin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vlcq0jo45s1gvr8du5ul09aui9